An Invitation to Showcase Zero-Proof Innovation on the World’s Biggest Stage MIAMI, FL / ACCESS Newswire / August 4, 2025 / In a bold and unprecedented move, Arkay Beverages, the pioneer of alcohol-free spirits, announces that it is opening its Times Square billboard to competitors – inviting zero-proof brands from around the world to join […]
(NASDAQ:DORM), Highlights (All comparisons are to the prior year period unless otherwise noted): Net sales of $541.0 million for the quarter, up 7.6% compared to $503.0 million Diluted earnings per share (“EPS”) of $1.91, up 25% compared to $1.53 Adjusted diluted EPS* of $2.06, up 23% compared to $1.67 Raises its full year guidance for
(NASDAQ:AGIO), First regulatory approval for PYRUKYND in thalassemia, evaluated under SFDA's Breakthrough Medicines Program Agios partnered with NewBridge Pharmaceuticals, a regional specialty company focused on the Middle East and North Africa, in 2024 to manage PYRUKYND commercialization in the Gulf Region CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a
(NASDAQ:SNDX), – $28.6 million of Revuforj(R) (revumenib) net revenue, representing 43% growth over 1Q25 – – $36.2 million of Niktimvo(TM) (axatilimab-csfr) net revenue reported by Incyte in first full quarter of launch; $9.4 million in collaboration revenue reported by Syndax – – sNDA in R/R mNPM1 AML granted Priority Review; PDUFA action date of October
(NasdaqGM:MRUS), UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics(R), Triclonics(R) and ADClonics(R)), today announced that the Company granted non-statutory stock options to two new employees as an inducement
Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update GlobeNewswire August 04, 2025 – $28.6 million of Revuforj(R) (revumenib) net revenue, representing 43% growth over 1Q25 – – $36.2 million of Niktimvo(TM) (axatilimab-csfr) net revenue reported by Incyte in first full quarter of launch; $9.4 million in collaboration revenue reported by Syndax –
Merus N.V. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire August 04, 2025 UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics(R), Triclonics(R) and ADClonics(R)), today announced that
Dorman Products, Inc. Reports Second Quarter 2025 Results and Raises Full Year 2025 Guidance GlobeNewswire August 04, 2025 Highlights (All comparisons are to the prior year period unless otherwise noted): Net sales of $541.0 million for the quarter, up 7.6% compared to $503.0 million Diluted earnings per share (“EPS”) of $1.91, up 25% compared to
Agios' PYRUKYND(R) (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia GlobeNewswire August 04, 2025 First regulatory approval for PYRUKYND in thalassemia, evaluated under SFDA's Breakthrough Medicines Program Agios partnered with NewBridge Pharmaceuticals, a regional specialty company focused on the Middle East and North Africa, in 2024 to manage PYRUKYND commercialization in the Gulf Region
US WorldMeds (USWM) reported the successful closing of the previously announced acquisition of Adaptimmune Therapeutics plc's (Adaptimmune) cell-therapy assets-including TECELRA® (afamitresgene autoleucel), lete-cel, afami-cel, and uza-cel. The acquisition was first announced on July28, 2025and has now been finalized. Under the terms of the Asset Purchase Agreement, USWM paid $55 million in cash at closing and